Nlrp6 overexpression inhibits lipid synthesis to suppress proliferation of hepatocellular carcinoma cells by regulating the AMPK-Srebp1c axis

doi:10.12122/j.issn.1673-4254.2024.10.09

Abstract

Abstract:

Objective To investigate the mechanism of Nlrp6 for regulating hepatocellular carcinoma (HCC) progression in light of lipid synthesis regulation. Methods Nlrp6 expression level in HCC tissues of different pathological grades was investigated using RNA-seq data from The Cancer Genome Atlas (TCGA) database, and its correlation with the patients' survival was analyzed with Kaplan-Meier survival analysis. HepG2 cells with adenovirus-mediated Nlrp6 overexpression or knockdown were treated with palmitic acid (PA), and the changes in lipid deposition and cell proliferation were evaluated using Oil Red O staining, CCK-8 assay, EdU staining, and colony formation assay. RT-qPCR and Western blotting were used to detect the changes in expression of lipid synthesis-related genes and the proteins in the AMPK-Srebp1c axis. In a mouse model of hepatic steatosis established in liver-specific Nlrp6 knockout mice by high-fat diet feeding for 24 weeks, liver fibrosis was examined with histological staining, and the changes in expressions of HCC markers and the AMPK-Srebp1c signaling pathway were detected. Results Nlrp6 expression was significantly reduced in HCC tissues with negative correlations with the pathological grades and the patients' survival (P<0.0001). In HepG2 cells, Nlrp6 overexpression significantly inhibited lipid deposition and cell proliferation, whereas Nlrp6 knockdown produced the opposite effects. Nlrp6 overexpression strongly suppressed the expression of lipid synthesis-related genes, promoted AMPK phosphorylation, and inhibited Srebp1c expression. The mice with liver-specific Nlrp6 knockout and high-fat feeding showed increased hepatic steatosis, collagen deposition, and AFP expression with reduced AMPK phosphorylation and increased Srebp1c expression. Conclusion Nlrp6 overexpression inhibits lipid synthesis in HCC cells by regulating the AMPK-Srebp1c axis, which might be a key pathway for suppressing HCC cell proliferation.

Key words: Nlrp6, hepatocellular carcinoma cells, proliferation, lipid synthesis, hepatic steatosis

Cuiyuan HUANG, Yunping SUN, Wenqiang LI, Li LIU, Wei WANG, Jing ZHANG. Nlrp6 overexpression inhibits lipid synthesis to suppress proliferation of hepatocellular carcinoma cells by regulating the AMPK-Srebp1c axis[J]. Journal of Southern Medical University, 2024, 44(10): 1910-1917.

Figures/Tables 6

Fig.1 Reduced Nlrp6 expression in liver tissues is associated with poor survival outcomes of hepatocellular carcinoma (HCC) patients. A: Nlrp6 expression levels in HCC patients with varying pathological grades based on RNA-seq and clinical data of patients from The Cancer Genome Atlas (TCGA) dataset. B: Kaplan-Meier survival curve analysis based on TCGA dataset (n=371). C: Spearman correlation analysis between Nlrp6 expression and tumor proliferation markers using TCGA dataset (n=371). D: Comparative analysis of Nlrp6, lipid metabolism, and proliferation-related gene expressions in HCC tissues (n=371) versus adjacent tissues (n=50) using TCGA dataset. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Fig.2 Nlrp6 overexpression inhibits lipid accumulation in HepG2 cells. A: Validation of Nlrp6 overexpression and knockdown (n=3). B: Oil Red O staining after stimulation with 0.5 μmol/L palmitic acid (PA) for 24 h. *P<0.05 vs Ad-NC; #P<0.05 vs Ad-shNC.

Fig.3 Nlrp6 overexpression inhibits proliferation of HepG2 cells. A: CCK-8 assay for detecting cell proliferation (n=5). B: Colony formation assay. C: EdU staining. **P<0.01 vs Ad-shNC; #P<0.05 vs Ad-NC.

Fig.4 Nlrp6 regulates HepG2 cell proliferation by modulating lipid metabolism. A: Q-PCR assay for assessing the effect of Nlrp6 down-regulation on expressions of genes related to lipid synthesis in HepG2 cells. B: Effect of Nlrp6 overexpression on expressions of genes related to lipid synthesis in HepG2 cells (n=3). *P<0.05 vs Ad-shNC; ##P<0.01 vs Ad-NC.

Fig. 5 The AMPK-Srebp1c axis mediates Nlrp6 overexpression-induced inhibition of HepG2 cell proliferation. A: Western blotting for assessing the effect of Nlrp6 downregulation on the AMPK-Srebp1c signaling pathway in HepG2 cells. B: Western blotting for assessing the effect of Nlrp6 upregulation on the AMPK-Srebp1c signaling pathway in HepG2 cells. *P<0.05 vs Ad-shNC; #P<0.05 vs Ad-NC.

Fig.6 Liver-specific Nlrp6 knockout promotes lipid metabolism disorder-induced injury via the AMPK-Srebp1c axis. A: HE staining, Masson staining and Sirius scarlet staining of mouse livers after modeling with high-fat diet (HFD) in wild-type mice (Loxp) and Nlrp6 liver-specific knockout mice (LKO). B: RT-qPCR for detecting expressions of the relevant genes in the liver tissues. C: Western blotting for assessing the effect of liver-specific NLRP6 knockout on the AMPK-Srebp1c signaling pathway. *P<0.05, **P<0.01 vs Loxp-HFD.

References 28

1	Naing C, Ni H, Aung HH, et al. Gene therapy for people with hepatocellular carcinoma[J]. Cochrane Database Syst Rev, 2024, 6(6): CD013731.
2	Su XR, Li YX, Ren YP, et al. A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation[J]. Biomedecine Pharmacother, 2024, 176: 116902.
3	Hu N, Li HY, Tao CC, et al. The role of metabolic reprogramming in the tumor immune microenvironment: mechanisms and opportunities for immunotherapy in hepatocellular carcinoma[J]. Int J Mol Sci, 2024, 25(11): 5584.
4	Urquijo-Ponce JJ, Alventosa-Mateu C, Latorre-Sánchez M, et al. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma[J]. World J Gastroenterol, 2024, 30(19): 2512-22.
5	Cao LQ, Xie YH, Fleishman JS, et al. Hepatocellular carcinoma and lipid metabolism: novel targets and therapeutic strategies[J]. Cancer Lett, 2024, 597: 217061.
6	Maurotti S, Geirola N, Frosina M, et al. Exploring the impact of lipid droplets on the evolution and progress of hepatocarcinoma[J]. Front Cell Dev Biol, 2024, 12: 1404006.
7	Zhang JQ, Zhang ZC, Wu ZF, et al. The switch triggering the invasion process: Lipid metabolism in the metastasis of hepatocellular carcinoma[J]. Chin Med J, 2024, 137(11): 1271-84.
8	Karin M, Kim JY. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives[J]. Mol Oncol, 2024: 13685.
9	Sharma BR, Kanneganti TD. Inflammasome signaling in colorectal cancer[J]. Transl Res, 2023, 252: 45-52.
10	Venuprasad K, Theiss AL. NLRP6 in host defense and intestinal inflammation[J]. Cell Rep, 2021, 35(4): 109043.
11	Huang CY, Liu QH, Tang Q, et al. Hepatocyte-specific deletion of Nlrp6 in mice exacerbates the development of non-alcoholic steatohepatitis[J]. Free Radic Biol Med, 2021, 169: 110-21.
12	Angosto-Bazarra D, Molina-López C, Pelegrín P. Physiological and pathophysiological functions of NLRP6: pro- and anti-inflammatory roles[J]. Commun Biol, 2022, 5(1): 524.
13	Chang LZ, Tian YY, Xu L, et al. Spotlight on NLRP6 and tumor research situation: a potential cancer participant[J]. J Immunol Res, 2023, 2023: 6613064.
14	Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer[J]. Cancer Immunol Res, 2017, 5(2): 94-9.
15	Chang LZ, Xu L, Tian YY, et al. NLRP6 deficiency suppresses colorectal cancer liver metastasis growth by modulating M-MDSC-induced immunosuppressive microenvironment[J]. Biochim Biophys Acta Mol Basis Dis, 2024, 1870(3): 167035.
16	Zhi F, Li BW, Zhang CX, et al. NLRP6 potentiates PI3K/AKT signalling by promoting autophagic degradation of p85α to drive tumorigenesis[J]. Nat Commun, 2023, 14(1): 6069.
17	Wang XY, Wu XW, Wang QQ, et al. NLRP6 suppresses gastric cancer growth via GRP78 ubiquitination[J]. Exp Cell Res, 2020, 395(1): 112177.
18	Normand S, Delanoye-Crespin A, Bressenot A, et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury[J]. Proc Natl Acad Sci U S A, 2011, 108(23): 9601-6.
19	Rivera-Esteban J, Muñoz-Martínez S, Higuera M, et al. Phenotypes of metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2024, 22(9): 1774-89. e8.
20	Feng TY, Li SQ, Zhao G, et al. DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis[J]. Cell Oncol, 2023, 46(5): 1235-52.
21	Banerjee A, Das D, Mukherjee S, et al. Comprehensive study of the interplay between immunological and metabolic factors in hepatic steatosis[J]. Int Immunopharmacol, 2024, 133: 112091.
22	Zhang XY, An T, Zhang XY, et al. DDX17 protects hepatocytes against oleic acid/palmitic acid-induced lipid accumulation[J]. Biochem Biophys Res Commun, 2022, 612: 169-75.
23	Yuan YM, Xu JT, Jiang QX, et al. Ficolin 3 promotes ferroptosis in HCC by downregulating IR/SREBP axis-mediated MUFA synthesis[J]. J Exp Clin Cancer Res, 2024, 43(1): 133.
24	Li N, Li XD, Ding YF, et al. SREBP regulation of lipid metabolism in liver disease, and therapeutic strategies[J]. Biomedicines, 2023, 11(12): 3280.
25	Wu KZ, Lin FZ. Lipid metabolism as a potential target of liver cancer[J]. J Hepatocell Carcinoma, 2024, 11: 327-46.
26	Feng SH, Han M, Zhou L, et al. NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis[J]. Cancer Sci, 2017, 108(1): 12-22.
27	Onorato AM, Fiore E, Bayo J, et al. SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism[J]. Liver Int, 2021, 41(7): 1677-93.
28	Hong J, Liu J, Zhang YN, et al. MiR-3180 inhibits hepatocellular carcinoma growth and metastasis by targeting lipid synthesis and uptake[J]. Cancer Cell Int, 2023, 23(1): 66.

[1]	Xiaohua CHEN, Hui LU, Ziliang WANG, Lian WANG, Yongsheng XIA, Zhijun GENG, Xiaofeng ZHANG, Xue SONG, Yueyue WANG, Jing LI, Jianguo HU, Lugen ZUO. Role of Abelson interactor 2 in progression and prognosis of gastric cancer and its regulatory mechanisms [J]. Journal of Southern Medical University, 2024, 44(9): 1653-1661.
[2]	Liangjun XUE, Qiuyu TAN, Jingwen XU, Lu FENG, Wenjin LI, Liang YAN, Yulei LI. MiR-6838-5p overexpression inhibits proliferation of breast cancer MCF-7 cells by downregulating DDR1 expression [J]. Journal of Southern Medical University, 2024, 44(9): 1677-1684.
[3]	Kai JI, Guanyu YU, Leqi ZHOU, Tianshuai ZHANG, Qianlong LING, Wenjiang MAN, Bing ZHU, Wei ZHANG. HNRNPA1 gene is highly expressed in colorectal cancer: its prognostic implications and potential as a therapeutic target [J]. Journal of Southern Medical University, 2024, 44(9): 1685-1695.
[4]	Yidan PANG, Ya LIU, Siai CHEN, Jinglei ZHANG, Jin ZENG, Yuanming PAN, Juan AN. Biological role of SPAG5 in the malignant proliferation of gastric cancer cells [J]. Journal of Southern Medical University, 2024, 44(8): 1497-1507.
[5]	Xiaofan CONG, Teng CHEN, Shuo LI, Yuanyuan WANG, Longyun ZHOU, Xiaolong LI, Pei ZHANG, Xiaojin SUN, Surong ZHAO. Dihydroartemisinin enhances sensitivity of nasopharyngeal carcinoma HNE1/DDP cells to cisplatin-induced apoptosis by promoting ROS production [J]. Journal of Southern Medical University, 2024, 44(8): 1553-1560.
[6]	Mengdong ZHENG, Yan LIU, Jiaojiao LIU, Qiaozhen KANG, Ting WANG. Effect of deletion of protein 4.1R on proliferation, apoptosis and glycolysis of hepatocyte HL-7702 cells [J]. Journal of Southern Medical University, 2024, 44(7): 1355-1360.
[7]	Huaxing HE, Lulin LIU, Yingyin LIU, Nachuan CHEN, Suxia SUN. Sodium butyrate and sorafenib synergistically inhibit hepatocellular carcinoma cells possibly by inducing ferroptosis through inhibiting YAP [J]. Journal of Southern Medical University, 2024, 44(7): 1425-1430.
[8]	Jincun FANG, Liwei LIU, Junhao LIN, Fengsheng CHEN. Overexpression of CDHR2 inhibits proliferation of breast cancer cells by inhibiting the PI3K/Akt pathway [J]. Journal of Southern Medical University, 2024, 44(6): 1117-1125.
[9]	Yongsheng XIA, Lian WANG, Xiaohua CHEN, Yulu ZHANG, Aofei SUN, Deli CHEN. TSR2 overexpression inhibits proliferation and invasion of gastric cancer cells by downregulating the PI3K/AKT signaling pathway [J]. Journal of Southern Medical University, 2024, 44(5): 913-919.
[10]	HUANG Qiuhu, ZHOU Jian, WANG Zizhen, YANG Kun, CHEN Zhenggang. MiR-26-3p regulates proliferation, migration, invasion and apoptosis of glioma cells by targeting CREB1 [J]. Journal of Southern Medical University, 2024, 44(3): 578-584.
[11]	ZHU Jin, OUYANG Xin, LIU Yu, QIAN Yemei, XIA Bin, SHI Yanan, YU Lifu. MiR-132-3p negatively regulates CAMTA1 to promote Schwann cell proliferation and migration and alleviates I-125 seeds-induced exacerbation of facial nerve injury in rats [J]. Journal of Southern Medical University, 2024, 44(3): 571-577.
[12]	SHEN Mengdi, ZHAO Na, DENG Xiaojing, DENG Min. High expression of COX6B2 in gastric cancer is associated with poor long-term prognosis and promotes cell proliferation and cell cycle progression by inhibiting p53 signaling [J]. Journal of Southern Medical University, 2024, 44(2): 289-297.
[13]	ZHANG Nuo, ZHANG Zhen, ZHANG Yulu, SONG Xue, ZHANG Xiaofeng, LI Jing, ZUO Lugen, HU Jianguo. PCID2 is highly expressed in gastric cancer and affects the prognosis by regulating cancer cell cycle and proliferation [J]. Journal of Southern Medical University, 2024, 44(2): 324-332.
[14]	Yonghua LI, Xinran XI, Meng ZHANG, Xun WU, Xianghai WANG. High expression of LINC00467 promotes proliferation and metastasis of lung adenocarcinoma cells by suppressing autophagy via inhibiting the AMPK/mTOR pathway [J]. Journal of Southern Medical University, 2024, 44(10): 1898-1909.
[15]	LIU Xuerou, YANG Yumei, CAI Hui, ZHANG Yaoshuai, FAN Fangtian, LI Xian, LI Shanshan. Aumolertinib inhibits proliferation, invasion and migration and promotes apoptosis of neuroblastoma cells by downregulating MMP2 and MMP9 expression [J]. Journal of Southern Medical University, 2023, 43(9): 1493-1499.